Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Table 1 Cell line properties and drug sensitivity

	HCC827	H1975	EBC-1	LUDLU
Properties
Histology	Adeno	Adeno	Squamous	Squamous
EGFR-status	Exon 19 deletion	L858R + T790M	Wild-type	Wild-type
cMET-status	Wild-type	Wild-type	Amplification	Wild-type
Drug sensitivity (µmol/L, IC50± SEM)
Cisplatin	8.39 ± 0.36	6.10 ± 0.07	16.52 ± 0.89	3.37 ± 0.19
Crizotinib	6.05 ± 0.11	4.00 ± 0.06	0.054 ± 0.002	8.12 ± 0.28

Cells were treated with cisplatin or crizotinib during 72 h. Drug sensitivity is given in µmol/L and given as IC₅₀± SEM of 3 separate experiments. EGFR: Epidermal growth factor receptor.